RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Ivabradine Added to Standard Therapy Improves Outcomes in Patients with Systolic HF
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 8
SP 10
OP 11
DO 10.1177/155989771008005
UL http://mdc.sagepub.com/content/10/8/10.2.abstract
AB Results of the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial [SHIFT; ISRCTN70429960] indicate that when added to standard therapy, ivabradine reduced heart rate and improved outcomes in subjects with systolic heart rate as early as 3 months [Swedberg K et al. Lancet 2010].